Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Lemieux is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Dr. Lemieux is a member of the Canadian Clinical Trial Group for quality of life in breast cancer. She is also a scientific committee member for the McPeak-Sirois research group.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and monitoring of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
J0-14
Québec, Québec
Canada G1S 4L8
Latest news
- Audet, DanièleEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 84596+1 418-682-7949daniele.audet@chudequebec.caDaniele.Audet@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-20
Québec, Québec
Canada G1S 4L8 - Bourgault, FanieEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 48275+1 418-525-4444, extension 82697fanie.bourgault@crchudequebec.ulaval.ca
1050 Chemin Ste-Foy
L3-27
Québec, Québec
canada G1S 4L8 - Carmichael, NathalieEmployeeHôpital Saint-Sacrement+1 418-682-7511, extension 84551+1 418-682-8046nathalie.carmichael@chudequebec.canathalie.carmichael@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
Québec, Québec
Canada G1S 4L8 - Desgagné, ManonEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 82086+1 418-682-8046manon.desgagne@chudequebec.camanon.desgagne@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-23
Québec, Québec
Canada G1S 4L8 - Desgagnés, ÈveEmployeeHôpital Saint-Sacrementeve.desgagnes@crchudequebec.ulaval.ca
1050 Chemin Sainte-Foy
K0-03
Québec, QC
Canada G1S 4L8 - Drolet, MarjolaineEmployeeMarjolaine.Drolet@crchudequebec.ulaval.ca
- Groleau, ÉmileEmployeeemile.groleau@crchudequebec.ulaval.ca
- Hogue, Jean-CharlesEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 82424jean-charles.hogue@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-26
Québec, Québec
Canada G1S 4L8 - Laflamme, ChristianEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 84591+1 418-682-7399christian.laflamme@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-24
Québec, Québec
Canada G1S 4L8 - Langlois, KristineEmployeekristine.langlois@crchudequebec.ulaval.ca
- Lépine, Marie-ClaudeEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension 67530marie-claude.lepine@crchudequebec.ulaval.ca
1401, 18e rue
G3.457
Québec, QC
Canada G1J 1Z4 - Levesque, Marie-HélèneEmployeeMarie-Helene.Levesque@chudequebec.ca
- Marcoux, Judith-ÉliseEmployeeHôpital Saint-Sacrement+1 418-682-7511, extension 84577+1 418-682-8046judith-elise.marcoux@chudequebec.cajudith-elise.marcoux@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-25
Québec, Québec
Canada G1S 4L8 - Martel, FrançoisEmployeefrancois.martel@crchudequebec.ulaval.ca
- Ouellet, IsabelleEmployeeHôpital Saint-Sacrement+1 418-682-7511, extension 84553+1 418-682-8046isabelle.ouellet@chudequebec.caisabelle.ouellet@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
Québec, Québec
Canada G1S 4L8 - Pagé, CarolineEmployeeHôpital Saint-Sacrement+1 418-682-7511, extension 82092+1 418-682-8046caroline.page@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
Québec, Québec
Canada G1S 4L8 - Pringalle, Justine Nicole NellyEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 84680justine.pringalle@chudequebec.cajustine.pringalle@crchudequebec.ulaval.ca
1050 Chemin Sainte-Foy
L3-18
Québec, QC
Canada G1S 4L8 - Tanguay, Marie-PauleEmployeeHôpital Saint-Sacrement+1 418-682-7511, extension 84532+1 418-682-8046marie-paule.tanguay@chudequebec.camarie-paule.tanguay@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
K3-21
Québec, Québec
Canada G1S 4L8 - Tellier, LucieEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 84680lucie.tellier@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-18
Québec, Québec
Canada G1S 4L8 - Vachon, EricEmployeeHôpital Saint-Sacrement+1 418-525-4444, extension 84728eric.vachon@chudequebec.caeric.vachon@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
L3-02
Québec, Québec
Canada G1S 4L8 - Vaillancourt, NathalieEmployeeHôpital Saint-Sacrement+1 418-682-7511, extension 82159nathalie.vaillancourt@chudequebec.canathalie.vaillancourt@crchudequebec.ulaval.ca
1050, chemin Sainte-Foy
K3-14
Québec, Québec
Canada G1S 4L8
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Journal ArticleBreast Cancer Res, 25 (1), 2023.
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)
Journal ArticleBreast Cancer Res Treat, 200 (1), 2023.
Adherence to CONSORT Guidelines and Reporting of the Determinants of External Validity in Clinical Oncology Randomized Controlled Trials: A Review of Trials Published in Four Major Journals between 2013 and 2015
Journal ArticleCurr Oncol, 30 (2), 2023.
Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial
Journal ArticleJACC Cardiovasc Imaging, 16 (3), 2023.
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Journal ArticleJ Clin Oncol, 2023.
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Journal ArticleJAMA, 327 (20), 2022.
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
Journal ArticleTher Adv Med Oncol, 14 , 2022.
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy
Journal ArticleJ Am Coll Cardiol, 77 (4), 2021.
Stress-buffering effect of social support on immunity and infectious risk during chemotherapy for breast cancer
Journal ArticleBrain Behav Immun Health, 10 , 2021.
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
Journal ArticleJNCI Cancer Spectr, 5 (5), 2021.
Active projects
- Age-related patterns in the experience of chemotherapy-induced peripheral neuropathy, from 2019-10-01 to 2024-09-30
- Elucidating patient and healthcare practitioner decision-making about chemotherapy-induced peripheral neuropathy-related, from 2023-04-01 to 2027-03-31
- Favoriser l'engagement des femmes ayant eu un cancer du sein dans les décisions concernant l'hormonothérapie adjuvante prolongée, from 2023-10-01 to 2027-05-31
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
- PALbociclib CoLlaborative Adjuvant Study (PALLAS study), from 2017-05-17 to 2025-12-25
- Perfectionism and psychosocial adjustment to cancer : A mixed methods study, from 2020-03-31 to 2024-03-31
- Personalized risk-stratified breast cancer follow-up care: a feasibility and acceptability study, from 2023-06-26 to 2026-06-30
- TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
- The effect of cannabinoid receptors on breast cancer survival, from 2022-09-01 to 2024-08-31
- Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31
Recently finished projects
- Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
- Projet pilote de l'utilisation d'une application pour le suivi et la prise en charge des effets secondaires associés aux traitements anti-néoplasiques oraux chez les patientes avec cancer du sein, from 2021-08-01 to 2023-07-31
- Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2023-12-01
- Utilisation de l'intelligence artificielle (IA) afin de prédire les résultats de biopsies faites pour les mammographies anormales avec comme but ultime de réduire le nombre de biopsies , from 2019-12-09 to 2021-12-08